Early AMD in one eye/no AMD the other eye
There were not enough participants in AREDS to a generate a recommendation. Perhaps results of Awh, Zanke and Kustra (2017) below may apply but it has not yet been studied. The study found that those with a specific genetic makeup may be harmed by taking the antioxidants (no zinc). There were no participants with early AMD in AREDS2. If your doctor has recommended that you take the supplement, see “Early AMD in both eyes” in The Guide.
References
- AREDS article: A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss
- AREDS2 article: Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
- Awh, Zanke and Kustra (2017): Progression From No AMD to Intermediate AMD as Influenced by Antioxidant Treatment and Genetic Risk: An Analysis of Data From the Age-Related Eye Disease Study Cataract Trial
- Vavvas & colleagues (2018) CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation
- AREDS/AREDS2 supplement sources: Eye Supplements for AMD and Where to Buy Vitamins
- Article about genetic testing with contact information: Genetic testing for AMD: first step toward personalized medicine in eye care
- AREDS 80mg zinc risk, 2018 research: CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation.